Few of studies investigated the effect of antihypertensives among working population. We aimed to describe the impact of hypertension with and without antihypertensives on hospitalizations because of cardiovascular diseases (CVDs) in the Japanese working population.
Original article
Hypertension is a global health issue, affecting 1.13 billion people worldwide. 1 In Japan, hypertension is defined as systolic/diastolic blood pressure (BP) persistently exceeding 140/90 mm Hg 2 and, as of 2010, as many as 43 million people (23 million men and 20 million women) were estimated to be affected. [3] [4] [5] According to a survey conducted by the Ministry of Health, Labour and Welfare once in 3 years, the number of hypertensive patients treated with any continuous medications has been assumed as 10.1 million individuals in Japan in 2014, with an increase of 1.04 million individual from the previous survey in 2011. 6 Persistent hypertension is a major risk factor for cardiovascular diseases (CVDs), [7] [8] [9] [10] which are the most common cause of death worldwide. 10 Globally, a number of studies have demonstrated a strong relationship between increasing BP levels and the risk of CVDs [11] [12] [13] [14] [15] -a trend that has also been observed in Japan. [16] [17] [18] [19] [20] Indeed, the World Health Organization considers hypertension to be the most important preventable cause of heart disease and stroke 21 ; therefore, effective management of hypertension is of paradigm importance. In fact, the number of Japanese people treated for hypertension and CVDs was around 1.2 million in 2008, 2011, and 2014, which accounted for more than 10% of all patients according to reports from the Ministry of Health, Labour and Welfare. [22] [23] [24] In addition to posing a clinical burden, CVDs also have a substantial indirect economic impact, causing morbidity-and mortality-related productivity losses, 25 so much so that their prevention in the working population may be of particular interest.
Although prior studies have explored the relationship between hypertension and CVDs in Japan, [16] [17] [18] [19] [20] a few of them have investigated the effect of antihypertensive treatments on patient outcomes. Furthermore, most of them were conducted in the community setting, where the mean age and incidence of CVDs were likely to be higher than those among people of working age. Therefore, this retrospective study was designed to describe the impact of hypertension severity and antihypertensive treatments on the risk of CVD-related hospital admissions in a worksite population.
METHODS
We performed a retrospective analysis of the anonymous health insurance claims database provided by Japan Medical Data Center, which contains data on approximately 3.8 million beneficiaries who are private sector employees and their dependents. The database covers 50 of approximately 1,500 Japanese health insurance societies (Kenpo) and contains detailed electronic individual-level records of health insurance claims. The data extraction period ran from 1 July 2007 to 31 July 2015. Characteristics related to patient, claim, physician and facility, and information related to diagnosis, procedure, drug, and health checkups were collected. In Japan, employers are legally required to provide annual health checkups for workers, and workers are likewise mutually obligated to participate in the health evaluations.
Study population
The analysis included individuals who met the following criteria: (i) had at least one health checkup including both systolic and diastolic BP readings between January 2008 and January 2015, (ii) were aged 40-64 years at their earliest checkup with both systolic and diastolic pressure readings (index date), (iii) were enrolled in the database continuously for at least 6 months before the index date (look-back period), and (iv) were enrolled in the database continuously for at least 6 months from the month following the index date (post-index period), e.g., a patient whose index date was 10 January 2009 had to remain enrolled in the database until at least 10 July 2009. Individuals were excluded from the study population if they had a history of physiciandiagnosed CVDs or secondary hypertension in the 6 months before the index date. CVDs (International Classification of Diseases, Tenth Revision [ICD-10]: I20-I25, I60-I67, I69) and secondary hypertension (ICD-10: I15) diagnoses were identified using ICD-10 diagnostic codes.
Individuals were classified into subgroups depending on their antihypertensive treatment history: treated (T) individuals were prescribed at least 1 antihypertensive drug during the look-back period, whereas previously untreated (UT) individuals had received no antihypertensive treatment during the look-back period. Drugs belonging to the following classes of the Anatomical Therapeutic Chemical Classification System (ATC-CS) were considered when determining previous treatment status: antihypertensives (ATC code C02), diuretics (ATC code C03), beta-blocking agents (ATC code C07), calcium channel blockers (ATC code C08), agents acting on the renin-angiotensin system (ATC code C09), and cardiovascular multitherapy combination products (ATC code C11).
The outcomes were compared in individuals with different BP readings at the index date. The subjects were classified into 6 BP levels according to the Japanese guidelines on hypertension 9 : optimal (<120/80 mm Hg), normal (120/80-129/84 mm Hg), high-normal (130/85-139/89 mm Hg), grade 1 hypertension (140/90-159/99 mm Hg), grade 2 hypertension (160/100-179/109 mm Hg), and grade 3 hypertension (≥180/110 mm Hg). BP levels at the index date were defined using either the systolic or diastolic reading with the higher grade reading taken into the final consideration.
Outcome definitions and statistical analysis
The main outcome of interest in this study was time from the index date to the first hospital admission due to a CVD. This outcome was defined as a diagnosis of CVD, identified by the aforementioned ICD-10 diagnostic codes, associated with procedure codes related to hospitalization as defined in the Japanese medical fee point tables.
Nonadjusted comparisons were conducted using Student's t test or analysis of variance to compare the means of continuous variables. For categorical variables, chi-square or Fisher's exact test (in case of insufficient theoretical size of subgroups) was used to compare the distributions. "Time-to-event"-type variables were studied using Kaplan-Meier analyses and presented graphically as Kaplan-Meier plots.
Multivariable adjusted Cox proportional hazard models were computed to generate hazard ratios (HRs) and 95% confidence intervals (CIs) of CVD-related hospitalization between BP levels, for each treatment status. One set of the models assessed the impact of baseline BP level, according to the Japanese guidelines on hypertension, on the risk of CVD-related hospitalization, considering the optimal BP level as the reference level in UT and T cohorts, and the optimal BP level of the UT cohort as the reference in merged UT/T cohort. The second set of models assessed the risk of CVD-related hospitalization in relation to the occurrence of hypertension at any given time, compared to those without hypertension, in both the UT and T cohorts. For the purpose of analyses and results presentation, levels "optimal, " "normal, " and "high-normal" were aggregated in the "nonhypertensive" group, and grade 1-3 hypertension in the "hypertensive" group.
The first set of models included the following variables as covariates: baseline BP level, the baseline covariates of demographic data at index date (i.e., age, gender, type of insurance) and health checkup data at index date (i.e., smoking habits, drinking habits, body mass index, high-density lipoprotein and low-density lipoprotein, triglycerides, fasting blood sugar and casual blood glucose, HbA1C, serum creatinine level, and urine protein) and the presence of comorbidities in the 6-month look-back period. Comorbidities of interest included type 1 and type 2 diabetes mellitus, dyslipidemia, sleep apnea, hyperuricemia and gout, asthma and chronic obstructive pulmonary disease, and kidney disease. Patients were considered diabetic if they satisfied at least 1 of the following 2 conditions in the 6-month look-back period: had a health checkup of fasting blood glucose ≥126 mg/dl or had a prescription for antidiabetic drugs (ATC code A10). A patient was considered to have dyslipidemia if they had a health checkup of low-density lipoprotein-cholesterol ≥140 mg/ dl, high-density lipoprotein-cholesterol <40 mg/dl or triglyceride ≥150 mg/dl, or if they had a prescription for antihypercholesterolemic drugs (ATC code C10AA, C10AB, C10AX09, C10BX, or C10BA). For other comorbidities, the following ICD-10 codes were used: G473 for sleep apnea, E790 and M10 for hyperuricemia and gout, J45 for asthma, J40-J44 and J47 for chronic obstructive pulmonary disease, and N00-N29 for kidney disease. The most appropriate covariates were selected following a process that included multicollinearity tests and stepwise method for each model. In the second set of models, the baseline BP level was replaced by a time-dependent variable reflecting BP change over the follow-up period. The use of a time-dependent variable was meaningful as BP level could have varied over time. 26 The time-dependent covariates included the following 3 states ( Figure 1 ): (i) hypertensive status, i.e., a period following a health checkup at which a patient was tested for hypertension, and the patient was considered hypertensive when found to have a systolic/diastolic BP of more than 140/90 mm Hg; (ii) nonhypertensive status, i.e., a period following a health checkup at which the BP reading was within the normal range and the patient was considered within the normal range if they were found to have a BP reading less than 140/90 mm Hg; and (iii) unknown status. A patient was attributed an unknown status when it was found that they had a more than 18-month interval between 2 checkups and no BP reading was recorded and it was, therefore, concluded that one could not assume that the patient remained within the same group (nonhypertensive or hypertensive). The nonhypertensive status was considered as reference.
Analyses were performed using SAS 9.3. A P value ≤0.05 was considered statistically significant for all analyses.
RESULTS

Baseline characteristics
The database contained data for 1,061,568 individuals who were aged between 40 and 64 years at index date and had more than 1 health checkup with both systolic and diastolic BP readings after January 2008, resulting in a total of 3,371,476 checkups. Of those, 813,612 individuals fulfilled the remaining eligibility criteria, providing data from 2,006,392 checkups. In 813,612 eligible individuals, approximately 85% of individuals were normotensive at index date (44.09% with optimal, 24.41% with normal, and 16.15% with high-normal BP level), whereas the remaining individuals presented with hypertension, with 11.89%, 2.76%, and 0.69% falling into grade 1, grade 2, and grade 3, respectively. The majority of individuals received no antihypertensive treatment during the look-back period prior to inclusion in the study, so the T subgroup included only 72,828 individuals, whereas over 10 times more individuals fell into the UT subgroup (740,784). Analyses related to comorbidities showed that the most prevalent comorbidity among both T and UT groups was dyslipidemia, for which the prevalence ranged from 2.55% to 5.51% in UT individuals and from 23.08% to 30.28% in T individuals. Detailed baseline characteristics and comorbidities of individuals by treatment group and BP status are presented in Tables 1 and 2 .
Hospitalization due to CVD
A mean follow-up from the index date was 957.3 days (2.6 years) in 740,784 UT individuals and 813.4 days (2.2 years) in 72,828 T individuals. Through the follow-up, 2,121 UT individuals (0.29%) were hospitalized due to a CVD and 470 (0.65%) among T individuals.
Among 72,828 T individuals, 57.7% of individuals were treated with antihypertensive treatments classified into one unique ATC code class during the look-back period (0.4% with drugs having ATC code C02, 1.4% with C03 drugs, 3.2% with C07 drugs, 21.3% with C08 drugs, and 31.4% with C09 drugs). The remaining 42.3% of T individuals were treated with treatments classified into multiple different ATC code classes during the look-back period. The CVD Figure 1 . Example of time-dependent variable setting for an individual. The figure presents an example of time-dependent variable setting for an individual including different status occurred during the follow-up period. Circled numbers indicate that the individual had health checkups with blood pressure readings. Depending on the readings results (indicated in the windows above), status of hypertension was attributed to each interval between checkups (indicated in the windows below). For example, the period following the first health checkup at which an individual was tested for nonhypertension was considered as the period with nonhypertensive status and the period following the second health checkup at which an individual was tested for hypertension was considered as the period with hypertensive status. When it was found that patients had a more than 18-month interval between 2 checkups and no blood pressure reading was recorded, unknown status was attributed after 18 months. Means of BMI, HDL, LDL, TG, fasting and casual blood glucose, HbA1c, and serum creatinine level, and proportions of smoking habits, drinking habits, and urine protein were calculated based on the available values from individuals in the dataset. Abbreviations: BP, blood pressure; BMI, body mass index. Table 1 . Continued hospitalization rate barely varied in T individuals treated with drugs classified into one unique ATC code class (varying from 0% to 1.5% depending on ATC code class). The rate more varied in T individuals treated with drugs classified into multiple different ATC code classes, varying from 0% to 4.2%.
The mean length of a hospitalization stay due to a CVD in overall individuals, including UT and T cohorts, was 10.02 (SD 17.40) days (11.06 (19.31) days in T cohort and 9.79 (16.95) days in UT cohort).
The impact of BP on CVD-related hospitalization
Kaplan-Meier plots of time to first hospitalization due to CVD are presented in Figure 2 . Kaplan-Meier curves observed in the UT group indicated that there were differences in the time to first hospitalization between BP levels during the follow-up period. Hospitalization risk was significantly lower for optimal BP (7-year probability of not being hospitalized for CVD reasons: 99.4%) compared to hypertensive individuals (7-year probability of not being hospitalized for CVD reasons: grade 1, 98.5%; grade 2, 97.6%; grade 3, 94.0%; P < 0.0001). In the T group, the plots for different BP levels crossed, which prevented us from obtaining conclusive results in this group.
Analysis of the impact that BP level at index date had on the probability of hospitalization due to CVD (Table 3) , using a Cox proportional hazards model, revealed that in UT individuals the probability of hospitalization increased with hypertension severity compared to individuals with , and grade 3 hypertension, respectively; P < 0.0001 for all tests). In contrast, BP level did not significantly affect CVD-related hospitalization probability among T individuals. When T and UT individuals were analyzed together in a single Cox regression model (Figure 3) , where UT individuals with optimal BP were used as reference, the probability of hospitalization increased with the severity of hypertension at index date in the UT group hypertension, respectively; P < 0.0001 for grade 1 and grade 3, and P = 0.0003 for grade 2). Point estimates of HRs were lower in normotensive/grade 1 and 2 hypertension-treated individuals compared to grade 2 hypertension untreated individuals. In addition, lower point estimates were observed in grade 3 hypertension treated individuals comparing to untreated individuals with the same grade.
In an analysis taking into account possible changes in BP over time, by inclusion as a time-dependent variable (Table 4) , UT individuals with hypertension at any given time point in the follow-up period had a significantly higher probability of hospitalization compared to individuals without hypertension at the same time point (HR: 1.74 [95% CI: 1.5; 2.01], P < 0.0001). In contrast, no statistically significant relationship between hypertension [25] [26] [27] [28] [29] , [30] [31] [32] [33] [34] , [35] [36] [37] [38] [39] , ≥40 kg/m 2 ), and HbA1c for the untreated group, and gender, age, diabetes, sleep apnea, smoking habits, uric protein, and HDL class (defined as <40, ≥40 mg/dl) for the treated group. Abbreviations: CI, confidence interval; HR, hazard ratio. and hospitalization at any given time was observed among T individuals in this analysis (HR: 1.14 [0.9; 1.44], P = 0.28).
DISCUSSION
There are a few cohort studies that have investigated the relationship between BP level and CVD, and the impact of treatment status of antihypertensive treatments on CVD in treated and untreated individuals. Therefore, the relationship between hypertension severity and the risk of admission to hospital due to a CVD was investigated in this study. In addition, the influence of antihypertensive treatment was considered. It has been found that the risk of CVD-related hospitalization increased with an increased level of hypertension in individuals who were not receiving treatment aimed at normalizing their BP level. However, antihypertensive treatment appeared to ablate that effect, with exception for grade 3 hypertension; therefore, hypertension severity did not influence hospitalization risk among individuals who were receiving antihypertensive medication. Specifically, point estimates related to CVD hospitalization risk were lower in normotensive/grade 1 and grade 2 hypertension treated individuals compared to grade 2 hypertension untreated individuals. Lower point estimates were also observed in grade 3 hypertension treated individuals comparing to untreated individuals with the same grade, suggesting that the protective effect of antihypertensive treatment may be effective in this relatively young worksite population.
Our results echo previous publications from Japan 27, 28 and other countries, [11] [12] [13] [14] [15] which demonstrated that, in untreated individuals, cardiovascular prognosis worsens with increasing hypertension severity. The outcomes of our research also support the beneficial effects of antihypertensive treatment in preventing CVD development reported in numerous earlier studies. 15, [29] [30] [31] [32] However, contrary to our findings, some previous observational studies from Japan have shown that individuals treated with antihypertensive medications had a higher cardiovascular risk compared to untreated individuals matched by BP level at baseline. 17, 18 Unlike our study that focused on working-age individuals (mean age of 47.91 years in the UT group and 53.68 years in the T group), these studies included patients of a very broad age range, some of whom were elderly (mean age of 55-60 years 17, 18 ). It is possible that in the older population, with perhaps more frequent and severe comorbidities, factors other than antihypertensive treatment become more important drivers of cardiovascular risk. Indeed, one of the aforementioned studies reported a rate of cardiovascular death as high as 5.1 per 1,000 person-years 17 -almost 5 times higher than the rate observed in our study (1.23 per 1,000 person-years), suggesting that the population included may have had relatively advanced CVD. Furthermore, it may be possible that these patients began antihypertensive treatment late in the disease process where arterial damage from persistent hypertension had already taken place. This could likely explain both the high cardiovascular death rate and the apparent little benefit from antihypertensive therapy compared with our findings.
Our study suggests that successful management of hypertension can be achieved in the working population. More than 60% of individuals treated with antihypertensives had their BP levels adequately controlled with measurements below 140/90 mm Hg noted at checkups. This trend was well aligned with previous studies reporting good BP level control in a substantial proportion of working-age patients (33.3%-49.9%). 3, 33 Given the dramatic improvement in hypertension control over the 30 years from 1980 to 2010, 3 our study suggests that further improvements in BP level management can be expected in the future. These changes are likely to be multifactorial, driven by the public becoming more aware of lifestyle factors that may increase the risk of CVD, earlier CVD diagnoses, and increasing availability of effective treatments.
A major strength of our study was the wealth of available source data, with health checkup readings of BP levels available for over a million individuals. This allowed us to obtain data from over 800,000 individuals, even after applying additional eligibility criteria-a large sample of the Japanese working population. Another strength of our study relates to the effective collection of longitudinal data. Individuals' BP level readings were followed for a mean of 944 days (2.6 years) and differences over time were accounted for by analyzing BP level as a time-dependent variable-an important advantage over prior related studies. 17 However, our research is not free from limitations. The diagnoses registered in an administrative database might not fully reflect reality, as physicians could manipulate the recorded diagnostic codes to ensure reimbursement. To address this issue, some additional health checkup data and medication histories were extracted to obtain reliable diagnoses of the studied diseases. Furthermore, some individuals in our study did not have regular health checkups and, thus, not all changes in BP levels could be accounted for in the timedependent model. 26 Therefore, the "unknown" BP status was created and applied to individuals with an over 18-month gap between health checkups. Lastly, the look-back period was referred to set subgroups (UT and T groups); therefore, patients defined as UT group might have started to take antihypertensives after the index date during the follow-up period. However, if significant number of participants in UT group started antihypertensive medication during the follow-up period, the observed difference in CVD hospitalization between T and UT group might be attenuated. This study adds quantitative evidence about the impact of hypertension on the risk of CVD-related hospitalization in the Japanese working population. Increasing severity of hypertension was associated with progressively higher risk of CVD-related hospitalization in untreated individuals. Individuals receiving antihypertensive treatment had lower CVD-related hospitalization risk compared to the untreated individuals among grade 2 or above hypertensive patients, suggesting that antihypertensive treatment had beneficial effects in this relatively young, working population. Data from routine health checkups may be useful for identifying individuals at risk of CVDs and assisting them with disease management in the early stages of hypertension.
